Client News: Jewish Hospital Plays significant role in clinical trial that leads to FDA approval of HeartMateII®

Jewish Hospital Plays significant role in clinical trial that leads to FDA approval of HeartMateII®

Based on the integral role Jewish Hospital played in the landmark HeartMate II® Destination Therapy Clinical Trial, Jewish Hospital announced today that the HeartMate II Left Ventricular Assist System (LVAS) has received FDA approval for Destination Therapy (DT), or long-term treatment option, for patients suffering from advanced-stage heart failure who are not eligible for heart transplantation.

Jewish Hospital remains among select cardiac centers in the nation to offer the state-of-the-art therapy to these advanced heart failure patients for whom there is a critical care need.

More info: http://bit.ly/5xILRc